Market Overview

Thoratec Announces Approval for HeartMate II in Japan

Related THOR
Thoratec Receives Approval From FDA For Full Expansion Of HeartMate III™ U.S. IDE Clinical Trial
Credit Suisse Reiterates Outperform, Raises Price Target On Thoratec On Updated LVAD Estimates

Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that the company has received approval from Japan's Ministry of Health, Labour and Welfare to market HeartMate II® ^ as a Bridge-to-Transplantation therapy for patients suffering from advanced heart failure.

Posted-In: News


Related Articles (THOR)

Around the Web, We're Loving...

Get Benzinga's Newsletters